COSCIENS Biopharma - CSCI EV/Sales Multiple

Public company logo of cosciensbio.com (CSCI)

COSCIENS Biopharma Inc. (CSCI) is pursuing global expansion of its endocrine pathology treatment portfolio through the development of Macrilen. This EV/Sales chart visualizes the market consensus on business valuation, where reflects the current value of the metric. While Liminal technology creates unique methods for combating fibrosis, current profits are offset by the costs of promoting drugs in the early stages of commercialization.

COSCIENS Biopharma Inc. - CSCI Enterprise Value-to-Revenue Ratio (period 07/04/2022 - 11/20/2026)

COSCIENS Bio - analytical breakdowns and key metrics (CSCI)

Initial company analysis:CSCI, cosciensbio.com
Mass-produced product of Aeterna Zentaris

This indicator compares the total enterprise value, including debt and subtracting cash, with annual revenue to assess the efficiency of revenue capitalization regardless of the financing structure. The EV/Revenue trend for COSCIENS Biopharma (CSCI) reflects market expectations amid low margin scalability, where high costs for promoting drugs in the early stages of commercialization constrain fundamental value growth.